Drugs / Xalacom
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 32 trials · 1 met primary | ||||||
| Phase 3 | NCT00219596 | Jun 2005 → Sep 2006 | ocular hypertension, open-angle glaucoma | Viatris Inc. | Completed | Met primary |
| Phase 3 | NCT00150267 | Feb 2002 → ? | ocular hypertension, open-angle glaucoma | Pfizer | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT04296916 | Apr 2020 → Oct 2024 | borderline glaucoma, myopia | Sun Yat-sen University | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Xalacom | “If necessary, latanoprost and timolol will be switched to Xalacom eye drops, timolol and alphagan will be switched to Combigan eye drops, timolol and brinzolamide will be...” NCT04296916 ↗ |
| Known as | LTFC | “BACKGROUND: A noninferiority trial was conducted to evaluate the efficacy of a single evening dose of fixed-combination latanoprost 50 μg/mL and timolol 0.5 mg/mL (Xalacom®;...” PMID 21851642 ↗ Aug 2011 |
| Route | Topical | “Xalacom eye drops” NCT04296916 ↗ |